Evaxion to present three-year phase 2 EVX-01 melanoma vaccine efficacy data at ESMO 2026

Evaxion flagged a potential data catalyst at ESMO 2026, outlining plans to present three-year phase 2 efficacy results for EVX-01 in advanced melanoma.

• The update includes an extension-trial readout on the durability of the immune response, including third-year EVX-01 monotherapy outcomes following earlier combination use with Keytruda.
• Prior two-year follow-up showed a 75% objective response rate, including four complete responses.
• 92% of responders remained in response with no relapses.
• The presentation is scheduled for Oct. 24, 2026, in Madrid, and the abstract focuses on sustained T-cell responses with durable disease control.